<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487903</url>
  </required_header>
  <id_info>
    <org_study_id>127-015</org_study_id>
    <nct_id>NCT00487903</nct_id>
  </id_info>
  <brief_title>Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems</brief_title>
  <official_title>A Phase 2 Trial of PB127 Myocardial Perfusion Echocardiography to Evaluate and Optimize Additional Ultrasound Imaging Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Point Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Point Biomedical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to evaluate various commercially available ultrasound&#xD;
      systems and to identify imaging parameters to be used with these systems (along with the&#xD;
      contrast agent PB127) as well as to further evaluate the safety of PB127.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinued PB127 development program for business reasons&#xD;
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of optimal machine settings and imaging parameters for myocardial perfusion for a variety of ultrasound imaging systems to be used in upcoming clinical trials</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PB127 for Injectable Suspension</intervention_name>
    <description>0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.</description>
    <other_name>CARDIOsphere®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Men and women&#xD;
&#xD;
          1. Normal volunteers (18 30 years old), with no history of CAD&#xD;
&#xD;
          2. Patients (≥ 18 years old) with known or suspected CAD, scheduled for or undergone&#xD;
             clinically indicated coronary angiography within 28 days prior to or following Study&#xD;
             Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to provide written informed consent&#xD;
&#xD;
          2. Women who are pregnant or lactating&#xD;
&#xD;
          3. Known hypersensitivity or known contraindication to:&#xD;
&#xD;
               1. Dipyridamole&#xD;
&#xD;
               2. Ultrasound contrast agents (including PB127 and excipients)&#xD;
&#xD;
               3. Blood, blood products, albumin, egg whites, or protein&#xD;
&#xD;
          4. Use of caffeine or xanthine containing products within the 24 hours prior to PB127&#xD;
             administration on Study Day 1&#xD;
&#xD;
          5. Previous exposure to PB127&#xD;
&#xD;
          6. Inadequate echocardiographic windows&#xD;
&#xD;
          7. Heart transplant&#xD;
&#xD;
          8. Known right to left shunt, including atrial septal defect&#xD;
&#xD;
          9. History of CABG&#xD;
&#xD;
         10. Current uncontrolled ventricular tachycardia, atrial fibrillation, atrial tachycardia,&#xD;
             or atrial flutter&#xD;
&#xD;
         11. Pacemaker or defibrillator&#xD;
&#xD;
         12. Unstable angina grade CCS Class IV severity with ongoing symptoms and/or ongoing&#xD;
             infusion of IV nitroglycerin&#xD;
&#xD;
         13. Second degree or greater heart block&#xD;
&#xD;
         14. Hypertension (SPB &gt;200 and/or DBP &gt;110 mmHg on two consecutive readings within 1 hour&#xD;
             prior to PB127 administration)&#xD;
&#xD;
         15. Hypotension (SPB &lt;90 mmHg on two consecutive readings within 1 hour prior to PB127&#xD;
             administration)&#xD;
&#xD;
         16. Severe aortic stenosis (&gt;100 mmHg peak transvalvar gradient or &lt;0.6 cm2 estimated&#xD;
             valve area)&#xD;
&#xD;
         17. Pulmonary edema within the 7 days prior to Study Day 1&#xD;
&#xD;
         18. Resting oxygen saturation of less than 90%&#xD;
&#xD;
         19. Q wave MI within the 7 days prior to Study Day 1&#xD;
&#xD;
         20. PTCA within the 28 days prior to Study Day 1&#xD;
&#xD;
         21. Chronic obstructive pulmonary disease or bronchospastic airway disease which, in the&#xD;
             opinion of the Investigator, is significant enough to contraindicate dipyridamole&#xD;
&#xD;
         22. Known history of severe pulmonary hypertension characterized by estimated pulmonary&#xD;
             artery systolic pressure of &gt;50 mmHg&#xD;
&#xD;
         23. Liver disease, characterized by or including one or more of the following&#xD;
&#xD;
               1. Elevated total bilirubin &gt;upper limit of normal&#xD;
&#xD;
               2. Currently elevated hepatic enzymes &gt;3X upper limit of normal&#xD;
&#xD;
         24. Medical conditions or other circumstances that would significantly decrease the&#xD;
             chances of obtaining reliable data or achieving the study objectives (i.e., drug&#xD;
             dependence, psychiatric disorder, dementia, or associated illness); extenuating&#xD;
             circumstances or medical conditions that make it unlikely that a patient can complete&#xD;
             the clinical trial or follow up evaluations; or other reasons for expected poor&#xD;
             compliance with the clinical investigator's instructions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Ehlgen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>POINT Biomedical Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midwest Cardiology Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>June 15, 2007</study_first_submitted>
  <study_first_submitted_qc>June 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2007</study_first_posted>
  <last_update_submitted>July 1, 2008</last_update_submitted>
  <last_update_submitted_qc>July 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tom Ottoboni, PhD/Chief Operating Officer</name_title>
    <organization>Point Biomedical Corp.</organization>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Echocardiogram</keyword>
  <keyword>Contrast</keyword>
  <keyword>Perfusion</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Normal volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

